| Rank |
Status |
Study |
| 1 |
Recruiting
|
Comparison of Pantoprazole and Ranitidine in Dyspepsia
| Condition: |
Dyspepsia |
| Interventions: |
Drug: Pantoprazole; Drug: Ranitidine |
| Outcome Measures: |
Visual analogue scale score; Need for additional drug |
|
| 2 |
Recruiting
|
TPI 287 in Breast Cancer Metastatic to the Brain
| Condition: |
Breast Cancer |
| Interventions: |
Drug: TPI 287; Drug: Dexamethasone; Drug: Benadryl; Drug: Ranitidine |
| Outcome Measure: |
Overall Response Rate |
|
| 3 |
Recruiting
|
Treatment of Orthostatic Hypotension in Autonomic Failure
| Conditions: |
Autonomic Failure; Orthostatic Hypotension |
| Interventions: |
Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: Inflatable abdominal binder; Device: inflatable abdominal binder (sham) |
| Outcome Measures: |
Increase in seated systolic blood pressure 1-hr post drug compared to baseline.; Increase in standing time 1-hr post drug compared to baseline |
|
| 4 |
Not yet recruiting
|
The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux
| Conditions: |
Eustachian Tube Dysfunction; Laryngopharyngeal Reflux |
| Interventions: |
Drug: Omeprazole; Drug: Ranitidine; Drug: Pantoprazole; Procedure: 24-Hour Diagnostic pH-Probe Test; Procedure: Laryngoscopy |
| Outcome Measure: |
Evidence of laryngopharyngeal reflux in patients complaining of ear fullness/pressure/pain |
|
| 5 |
Recruiting
|
Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
| Conditions: |
Pharmacokinetics; Voriconazole |
| Intervention: |
Drug: Midazolam/Ranitidine/Esomeprazole |
| Outcome Measures: |
Voriconazole steady-state pharmacokinetics; Voriconazole drug metabolizing enzyme activity |
|
| 6 |
Recruiting
|
Clinical Trial Corticoids For Empyema And Pleural Effusion In Children
| Conditions: |
Parapneumonic Pleural Effusion; Empyema |
| Interventions: |
Drug: Dexamethasone; Drug: Placebo |
| Outcome Measures: |
time to resolution; number of children with complications.; Number of children with complications attributable to corticoids |
|
| 7 |
Unknown †
|
Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
| Condition: |
Poisoning |
| Interventions: |
Drug: Chlorphenamine and Ranitidine; Drug: Paracetamol |
| Outcome Measures: |
Attenuation of NAC induced vasodilatation by histamine antagonists (H1 and H2 antagonists) and/or paracetamol; Inhibition of the inflammatory cascade contributes to a paracetamol mediated protective role against NAC adverse reactions. |
|
| 8 |
Unknown †
|
Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
| Condition: |
Dyspepsia |
| Intervention: |
Procedure: gastroscopic examination |
| Outcome Measures: |
Incidence of H. pylori Clarithromycin resistance gene; Characteristic of H. pylori clarithromycin resistant gene mutation |
|
| 9 |
Unknown †
|
Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study
| Condition: |
Helicobacter Pylori Infection |
| Interventions: |
Drug: Group A: NCA 600 mg+antibiotics; Drug: Group B: antibiotic treatment (control) |
| Outcome Measure: |
To evaluate the usefulness of NAC as pre-treatment attempt associated with a culture-guided antibiotic therapy as rescue therapy after multi-attempts antibiotic failure |
|
| 10 |
Recruiting
|
Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
| Condition: |
Glioblastoma Multiforme (GBM) WHO Grade IV |
| Intervention: |
Drug: Cabazitaxel |
| Outcome Measures: |
Response including SD, PR or CR determined by MRI (modified RANO criteria); Overall and progression-free survival; Safety and tolerability; Pharmacokinetics data concerning drug interactions (i.e. CYP3A induction); Quality of life and neurocognitive functioning |
|
| 11 |
Recruiting
|
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
| Conditions: |
Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer |
| Intervention: |
Drug: carboplatin |
| Outcome Measures: |
To determine if patients have lower rates of hypersensitivity reactions compared to those treated with standard infusion carboplatin.; Determine the rate of successful planned treatment completion of carboplatin in each group; Perform a cost-identification analysis of extended infusion carboplatin to estimate the cost per hypersensitivity reaction prevented.; Perform exploratory analyses to correlate hypersensitivity rate to history of atopy, prior drug allergies, number of lifetime platinum cycles, duration since last platinum, and concomitant chemotherapy agent. |
|
| 12 |
Not yet recruiting
|
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
| Condition: |
Breast Neoplasms |
| Interventions: |
Drug: Vintafolide 2.5 mg; Drug: Paclitaxel 80 mg/m^2; Drug: Etarfolatide; Drug: Folic acid; Drug: Premedication for Paclitaxel |
| Outcome Measures: |
Progression Free Survival (PFS); Objective Response Rate (Complete Response [CR] + Partial Response [PR]); Clinical Benefit Rate (CR + PR + Stable Disease [SD] for >=6 months); Overall Survival (OS) |
|
| 13 |
Recruiting
|
MAGIC vs. CROSS Upper GI. ICORG 10-14, V3
| Conditions: |
Adenocarcinoma of the Oesophagus; Adenocarcinoma of the Oesophago-gastric Junction; Oesophageal Tumours; Junctional Tumours; Oesophageal Cancer |
| Interventions: |
Drug: Epirubicin; Drug: Cisplatin; Drug: 5 Flourouracil/ Capecitabine; Radiation: (41.4 Gy/23 fractions); Drug: Paclitaxel; Drug: Carboplatin |
| Outcome Measure: |
Overall survival |
|
| 14 |
Recruiting
|
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
| Condition: |
Neoplasms |
| Interventions: |
Drug: Paclitaxel; Drug: Copanlisib (BAY80-6946) |
| Outcome Measures: |
Adverse event collection; Maximum tolerated dose, measured by adverse event profile; Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed); Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed); Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed); Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed); Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed); Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed); Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed); Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed); Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed); Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed); Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 - 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only); Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel; Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel; Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel; Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel; Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel; Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel; Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel; Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15; Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15; Number of patients with mutational status; Tumor Response as measured by RECIST 1.1 criteria |
|
| 15 |
Recruiting
|
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
| Conditions: |
Non-small Cell Lung Cancer; Advanced Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer |
| Interventions: |
Drug: Paclitaxel; Drug: Carboplatin; Drug: Hydroxychloroquine; Drug: Bevacizumab |
| Outcome Measures: |
Antitumor activity, as measured by tumor response rate of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer; Time to progression; Survival; Overall survival; Toxicity of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer |
|
| 16 |
Unknown †
|
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
| Conditions: |
Brain and Central Nervous System Tumors; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor |
| Interventions: |
Biological: filgrastim; Biological: lenograstim; Biological: pegfilgrastim; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: ifosfamide; Drug: paclitaxel |
| Outcome Measures: |
Maximum tolerated dose of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (phase I); Response rates (phase I); Failure-free survival (phase I); Utility of positron emission tomography scanning after Gem-TIP chemotherapy (phase I); Degree of dose intensification achieved with Gem-TIP chemotherapy relative to a previous Medical Research Council study with TIP alone (phase II) |
|
